Conditions: Glaucoma
Keywords: glaucoma impression cytology ocular surface changes prostaglandins
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 58
Healthy volunteers: no

Brief summary:
To determine whether one glaucoma eye drop is less likely to cause changes to the surface of the eye (conjunctiva) than another. The two different prostaglandins are Xalatan and Travatan Z.

Detailed description:
Two groups will be entered into this study: group 1 will be naive to treatment and group 2 will be using Xalatan for at least one month before enrollment. Both groups will be using one drop at bedtime of Xalatan in the right eye and one drop at bedtime of Travatan Z in the left eye. Both of these drops are presently on the market and approved by the FDA for treatment of lowering eye pressure. Because this study will be masked, the examining clinician will not know what study drop each patient has been using.

Arms:
arm 1: Naive to glaucoma therapy medical or surgical. All patients will receive Xalatan in the right eye and Travatan Z in the left eye. arm 2: Patients currently on Xalatan at least one month. All patients will receive Xalatan in the right eye and Travatan Z in the left eye.

Interventions: intervention 1: Xalatan intervention 2: Travatan Z
Intervention descriptions: intervention 1: one drop of Xalatan Ophthalmic Solution instilled in right eye at bedtime intervention 2: one drop of Travatan Z Ophthalmic Solution instilled in left eye at bedtime

Protocol document: